Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Combining Targeted Therapy With Immunotherapy Using Imatinib Plus Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients

NCT00585221 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT00585221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00585221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Combining Targeted Therapy With Immunotherapy Using Imatinib Plus Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients
Lead sponsor
University of Utah
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2007
Completion date
July 31, 2009
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer brain, gastrointestinal stromal tumors, solid tumors